A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC 715969, IND 10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL).

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Alemtuzumab (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Filgrastim; Folinic acid; Imatinib; Mercaptopurine; Methotrexate; Vincristine
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
20 Apr 2011 Planned end date changed from 1 Oct 2005 to 1 May 2017 as reported by ClinicalTrials.gov.
12 Jan 2010 Planned number of patients changed from 254 to 282 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com